Phase 2 Evidence and Impact Analysis
I am scoring all 94 articles independently across five dimensions, then flagging key quantitative findings, limitations, equity implications, and evidence maturity verdicts. I will present scores for the top-tier articles (triage score ≥7) in full detail, with abbreviated entries for lower-tier articles to maintain usability.
Full Dimension Scores — High-Priority and Notable Articles
Article 1 — Multimodal AI in Oral Cancer (PMID 42999821) Systematic review; peer-reviewed
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Multimodal AI for cancer diagnostics is an active field; systematic synthesis adds value but doesn't break new ground |
| Clinical Relevance | 6 | Diagnostic accuracy improvements are meaningful, but no head-to-head RCT data or prospective validation |
| Population Reach | 5 | Oral cancer: ~390,000 new cases/year globally; meaningful but not highest-burden disease |
| Implementation Speed | 4 | AI tools require regulatory clearance, clinician training, and workflow integration |
| Evidence Strength | 6 | Systematic review (PRISMA) is high-quality design, but abstract only; underlying primary studies likely heterogeneous |
Key quantitative result: Not specified beyond "multimodal consistently outperforms unimodal" in AUC and survival prediction — no pooled AUC or effect size reported in abstract. External validation: Depends on included studies; unknown from abstract. Main limitation: Abstract-only access; underlying study heterogeneity likely high; no meta-analytic pooling reported. Equity: Oral cancer disproportionately affects South/Southeast Asian populations (tobacco, betel nut use) and low-resource settings where AI tools may not be accessible. Evidence Maturity: Revised → Validated (systematic review synthesis, not exploratory, but not practice-changing without prospective confirmation)
Article 2 — Orforglipron ATTAIN Phase 3 (PMID 42999545) RCT (Phase 3); peer-reviewed; human
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Orforglipron is an oral non-peptide GLP-1 agonist — first oral small-molecule in class entering Phase 3; clinically distinct from injectable GLP-1 RAs |
| Clinical Relevance | 8 | Phase 3 RCT with HRQoL and functional outcomes in obesity; oral route addresses major adherence barrier |
| Population Reach | 9 | Obesity affects ~1 billion people globally; oral formulation could dramatically expand access |
| Implementation Speed | 7 | Phase 3 data supports regulatory submission; oral route removes cold-chain/injection barrier |
| Evidence Strength | 7 | Dual Phase 3 RCTs (ATTAIN-1, ATTAIN-2) are gold-standard design; abstract-only limits full assessment of effect sizes and adverse events |
Key quantitative result: "Substantial body weight reduction" and HRQoL improvements — specific percentage weight loss not stated in abstract. External validation: Two independent trial arms (ATTAIN-1 and ATTAIN-2) provide internal replication. Main limitation: Abstract-only; heterogeneous psychosocial effects across trials; long-term cardiovascular outcomes not yet reported. Equity: Oral formulation particularly beneficial for patients in low-resource settings or with needle phobia; could reduce health system burden of injection training. Evidence Maturity: Confirmed → Potentially Practice-Changing
Article 3 — SBRT + Immune Checkpoint Inhibitors for NSCLC (PMID 42999638) Meta-analysis; n=1,096; peer-reviewed; human
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | SBRT+ICI combination is established as a research concept; meta-analysis adds synthesis but concept is not new |
| Clinical Relevance | 6 | Statistically significant DCR, but sensitivity analyses show fragility; "low certainty of evidence" per authors |
| Population Reach | 8 | NSCLC is the leading cause of cancer death globally; ~2 million new cases/year |
| Implementation Speed | 5 | Low certainty evidence limits near-term adoption; heterogeneity in stages/intent is a barrier |
| Evidence Strength | 6 | Meta-analysis with reconstructed IPD is a strength; n=1,096 is reasonable; but heterogeneity and sensitivity concerns are significant |
Key quantitative result: DCR (disease control rate) statistically significant, but sensitive to individual study removal — no pooled OR or HR in abstract. External validation: Reconstructed IPD from prior trials; no independent external validation dataset. Main limitation: Marked heterogeneity across disease stages and treatment intents; low certainty of evidence per authors' own conclusion. Equity: NSCLC disproportionately affects smokers in lower-SES groups and high-incidence Asian populations; combination may be limited to well-resourced centers with SBRT capability. Evidence Maturity: Revised downward → Exploratory (authors themselves conclude low certainty; "potentially practice-changing" overstates it)
Article 4 — CEACAM5-Targeted Therapies Review (PMID 42999607) Narrative review; medium confidence
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | CEACAM5 target is established; review discusses Phase III failure (CARMEN-LC03), which is important negative signal |
| Clinical Relevance | 5 | Primarily forward-looking; Phase III failure means direct patient care impact is limited currently |
| Population Reach | 6 | Epithelial malignancies (colorectal, lung, gastric) are high-burden; but current patient selection failure limits reach |
| Implementation Speed | 3 | Phase III failure = significant setback; next-gen strategies are preclinical |
| Evidence Strength | 3 | Narrative review with medium confidence; lowest evidence tier |
Key quantitative result: None (narrative review). Main limitation: Narrative review design; no meta-analytic synthesis; Phase III failure context. Equity: N/A at this stage. Evidence Maturity: Confirmed → Exploratory
Article 5 — BMI and Ramadan Fasting in T2DM (PMID 42999643) Survey study (design unspecified); n=6,530; peer-reviewed
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Extends prior DaR survey work; confirms safety across BMI strata specifically |
| Clinical Relevance | 7 | Directly applicable to Muslim patients with T2DM — real-world safety question for >1.8 billion Muslims globally |
| Population Reach | 7 | 500 million Muslims with diabetes; previously underserved by RCT-based guidance |
| Implementation Speed | 7 | No new drugs or devices needed; guideline update could follow directly |
| Evidence Strength | 5 | Large observational n=6,530; self-reported survey; design unspecified; medium classification confidence |
Key quantitative result: No significant differences in adverse events across BMI categories during Ramadan fasting. Main limitation: Survey design; self-reporting bias; no laboratory safety data; unspecified study design. Equity: Directly serves a systematically underrepresented Muslim population in clinical trial evidence; major equity win if findings are reliable. Evidence Maturity: Confirmed → Validated (practical guidance value, but not randomized)
Article 6 — BTKi in Indian CLL Patients (PMID 42999795) Retrospective; n=41; peer-reviewed
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | BTKi efficacy in CLL is established; Indian real-world data adds regional context |
| Clinical Relevance | 5 | Adherence findings are actionable, but small n limits generalizability |
| Population Reach | 5 | CLL ~200,000 cases/year globally; India-specific data valuable for large population |
| Implementation Speed | 6 | Adherence strategies could be implemented now |
| Evidence Strength | 4 | Retrospective, single-center, n=41; high confidence classification |
Evidence Maturity: Confirmed → Validated (with important caveats on sample size)
Article 7 — BAL cfDNA-Guided Lazertinib in EGFR-Mutant NSCLC (PMID 42999407) Phase II prospective trial; n=128; peer-reviewed
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | BALiquid as EGFR genotyping platform for neoadjuvant lazertinib is genuinely novel |
| Clinical Relevance | 7 | Addresses a real gap: tissue unavailability for molecular testing in potentially resectable NSCLC |
| Population Reach | 7 | EGFR-mutant NSCLC: ~200,000–300,000 patients/year globally (higher in Asia) |
| Implementation Speed | 5 | Phase II only; needs Phase III confirmation before standard adoption |
| Evidence Strength | 6 | Prospective Phase II; n=128 is modest; abstract-only |
Key quantitative result: "Meaningful antitumor activity, favorable surgical outcomes, acceptable safety profile" — specific pCR or ORR not stated. Main limitation: Phase II; single-arm likely; abstract-only; no comparison arm stated. Equity: Particularly impactful in Asia (highest EGFR mutation prevalence); could benefit patients who cannot undergo CT-guided biopsy. Evidence Maturity: Confirmed → Validated (Phase II prospective with n=128)
Article 8 — Lung Cancer Screening in Rural Appalachia (PMID 42999622) QI intervention; design unspecified; peer-reviewed
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | QI interventions for screening uptake are well-established; Appalachia setting adds specificity |
| Clinical Relevance | 7 | Directly addresses mortality-reducing screening in highest-risk geographic population |
| Population Reach | 6 | Rural Appalachia is ~25 million people with disproportionate lung cancer mortality |
| Implementation Speed | 7 | Community-based, low-tech; implementable with existing infrastructure |
| Evidence Strength | 4 | QI study, design unspecified, no randomization, medium confidence |
Equity: Strongly equity-positive: targets one of the most underserved, highest lung cancer mortality populations in the US. Evidence Maturity: Revised → Exploratory (design unclear, no comparator)
Article 9 — Label-Free ML Multi-Cancer Urine/Plasma Metabolite Panel (PMID 42999273) Preprint; cohort study; n=4,105; human
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Label-free ML approach on 4-metabolite panel across 8 cancer types is genuinely novel |
| Clinical Relevance | 5 | Early-stage discovery; clinical utility not yet demonstrated prospectively |
| Population Reach | 8 | Multi-cancer detection from urine/plasma = potentially universal screening tool |
| Implementation Speed | 3 | Preprint; needs peer review, prospective validation, regulatory pathway |
| Evidence Strength | 5 | Large n=4,105; case-control design; preprint — capped at 7, but case-control limits causal inference; cap applied |
Key quantitative result: "Evaluated survival association and predictive values across prevalence" — no specific AUC or sensitivity/specificity in abstract. Main limitation: Preprint; case-control (not prospective); specific performance metrics not in abstract; "label-free" approach needs methodologic scrutiny. Equity: Non-invasive urine sample could democratize cancer screening globally if validated. Evidence Maturity: Confirmed → Exploratory
Article 10 — CTTN Amplification in HNSCC (PMID 43000090) Cohort/bioinformatic study; peer-reviewed; human
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | CTTN as prognostic biomarker in HNSCC is moderately novel |
| Clinical Relevance | 4 | Biomarker discovery only; no therapeutic intervention tested |
| Population Reach | 5 | HNSCC ~900,000 new cases/year globally |
| Implementation Speed | 3 | Biomarker needs prospective validation and assay standardization |
| Evidence Strength | 4 | Bioinformatic/cohort; no sample size in abstract; abstract only |
Evidence Maturity: Confirmed → Exploratory
Article 11 — GLP-1 Therapy: Strength and Function Monitoring (PMID 43000186) Review/commentary on RCT evidence; peer-reviewed; human
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | "Functional discordance" framework is a novel clinical construct for GLP-1 monitoring |
| Clinical Relevance | 8 | Directly applicable to millions on GLP-1 therapy; raises clinically important question about muscle function vs. mass |
| Population Reach | 9 | GLP-1 therapy now used by 10s of millions globally |
| Implementation Speed | 7 | Clinical monitoring protocol could be adopted now with existing tools |
| Evidence Strength | 5 | Review article; primary evidence comes from cited trials; "none of 35 body-composition trials measured objective physical function" is itself a key finding |
Key quantitative result: 2026 review of 35 body-composition trials found none measured objective physical function. Equity: Older adults and those with pre-existing sarcopenia are highest risk; this group is often underrepresented in GLP-1 trials. Evidence Maturity: Revised → Validated (synthesizes existing RCT data to generate actionable monitoring guidance)
Article 12 — COPD and CAR-T Survival in LBCL (PMID 43000021) Cohort study; n=173; peer-reviewed; human
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | COPD as a negative prognostic factor in CAR-T is not widely studied |
| Clinical Relevance | 7 | Directly informs patient selection and pre-treatment optimization for CAR-T |
| Population Reach | 5 | R/R LBCL treated with CAR-T: ~10,000–15,000 patients/year in high-income countries |
| Implementation Speed | 7 | COPD assessment is already standard; could immediately influence eligibility criteria |
| Evidence Strength | 5 | Retrospective cohort; n=173; abstract only |
Key quantitative result: COPD associated with inferior OS — no HR or specific OS difference stated. Evidence Maturity: Confirmed → Validated
Article 13 — Rare Cancers + ICI with Lung/Liver Metastases (NCI/SWOG S1609) (PMID 42999803) Retrospective; NCI/SWOG multicenter; peer-reviewed; human
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Lung+liver met combination as prognostic factor in ICI for rare tumors extends known melanoma/NSCLC data |
| Clinical Relevance | 6 | Informs patient counseling and trial stratification; multicenter NCI/SWOG data lends credibility |
| Population Reach | 5 | Rare tumors by definition; but NCI/SWOG dataset includes diverse histologies |
| Implementation Speed | 6 | Stratification factor could be adopted in trial design immediately |
| Evidence Strength | 5 | Retrospective; sample size unstated in abstract; multicenter is a strength |
Evidence Maturity: Confirmed → Validated
Article 14 — GLP-1 RAs on Hyperuricemia and Gout (PMID 43000185) Meta-analysis; n=942; peer-reviewed
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | GLP-1 RAs for gout/uric acid is a secondary benefit that is underappreciated |
| Clinical Relevance | 7 | Gout affects ~40 million people globally; GLP-1 patients often have comorbid gout |
| Population Reach | 7 | Large overlap between GLP-1-eligible and gout populations (T2DM, obesity, CKD) |
| Implementation Speed | 7 | No new prescription needed; awareness change only |
| Evidence Strength | 6 | Meta-analysis; n=942 is modest; mechanism appears mediated by weight loss |
Key quantitative result: Modest reductions in serum uric acid; lower incidence of gout flares and hyperuricemia; largely weight-loss mediated. Limitation: Small total n; likely heterogeneous GLP-1 agents; confounding by weight loss makes direct uric acid effect unclear. Equity: Gout disproportionately affects Pacific Islanders, Black men, and lower-SES groups — potential benefit for underserved populations already on GLP-1 for diabetes/obesity. Evidence Maturity: Confirmed → Potentially Practice-Changing
Articles 15–24 (abbreviated scoring)
| # | PMID | Article | Novelty | Clin. Relevance | Pop. Reach | Impl. Speed | Evid. Strength | Maturity |
|---|---|---|---|---|---|---|---|---|
| 15 | 43000053 | Father-Inclusive Perinatal Obesity Prevention RCT | 6 | 6 | 6 | 6 | 6 | Validated |
| 16 | 42999757 | Predictive Analytics to Reduce Clinician Burnout | 5 | 6 | 7 | 6 | 6 | Potentially Practice-Changing |
| 17 | 42999126 | Multiple Myeloma PDX Genomic Characterization (Preprint) | 6 | 3 | 4 | 2 | 3 | Exploratory |
| 18 | 42999620 | MYH11 Stemness and Immunotherapy Resistance in NSCLC | 6 | 3 | 5 | 2 | 4 | Exploratory |
| 19 | 43000212 | Circulating Tsukushi Predicts Sarcopenia | 7 | 6 | 6 | 4 | 6 | Validated |
| 20 | 43000150 | ALL Treatment in Older Adults — Japan Review | 4 | 5 | 5 | 3 | 2 | Exploratory |
| 21 | 42999838 | Lab Triage Model for HCC Early Detection | 6 | 6 | 6 | 5 | 5 | Exploratory |
| 22 | 42999444 | SF3B1 Mutation and lncRNA Peptides (Preprint) | 7 | 2 | 3 | 1 | 3 | Exploratory |
| 23 | 42999669 | Sparsentan First-Line in IgAN (SPARTAN) | 6 | 8 | 6 | 7 | 5 | Validated → strong candidate |
| 24 | 43000110 | AI in Glaucoma Diagnosis — 10-Year Review | 5 | 5 | 7 | 5 | 6 | Potentially Practice-Changing |
Articles 25–94 (abbreviated, scores informed by triage metadata and design)
| PMID | Short Title | Novelty | Clin.Rel. | Pop.Reach | Impl. | Evid. | Maturity |
|---|---|---|---|---|---|---|---|
| 42999628 | Atezolizumab dose and outcomes | 5 | 5 | 6 | 5 | 5 | Exploratory |
| 42999578 | MASLD burden in EU tertiary care | 5 | 5 | 7 | 4 | 6 | Validated |
| 42999395 | Incretins vs metreleptin in lipodystrophy | 7 | 6 | 3 | 5 | 4 | Validated |
| 42999819 | Molecular Profiling in Asia | 4 | 5 | 7 | 3 | 2 | Exploratory |
| 43000203 | Apheresis algorithm for CAR-T (ACIT001) | 5 | 6 | 4 | 6 | 5 | Exploratory |
| 42999844 | Cancer Nanovaccines Review | 5 | 4 | 6 | 2 | 3 | Exploratory |
| 43000069 | Semaglutide and motivation in MDD | 7 | 5 | 6 | 3 | 3 | Exploratory |
| 43000189 | Gut microbiome responses to tirzepatide vs semaglutide | 6 | 4 | 6 | 3 | 4 | Exploratory |
| 42999331 | Cannabis phytoligands as EGFR inhibitors (preprint) | 4 | 1 | 3 | 1 | 2 | Exploratory |
| 42999863 | Stem Cell Research in Sepsis — bibliometric | 3 | 3 | 5 | 2 | 2 | Validated (bibliometric) |
| 42999634 | Real-world NSCLC treatment patterns China | 4 | 5 | 7 | 4 | 5 | Validated |
| 43000086 | Sirtuins in Senescence and CVD | 6 | 3 | 7 | 2 | 2 | Exploratory |
| 43000109 | RNA m5C in cancer therapy resistance | 6 | 4 | 6 | 2 | 3 | Validated |
| 43000031 | Urinary Incontinence and Sarcopenia in older adults | 5 | 5 | 7 | 5 | 5 | Validated |
| 42999852 | Platelet-Tumor Interactions Review | 5 | 4 | 6 | 2 | 2 | Exploratory |
| 42999830 | Stem Cell EVs in Bladder Cancer | 5 | 3 | 5 | 1 | 2 | Exploratory |
| 42999878 | Osteoradionecrosis after reirradiation (n=3,278) | 6 | 7 | 5 | 6 | 7 | Potentially Practice-Changing |
| 42999747 | ALK-PROTAC nanoparticles for NSCLC resistance | 6 | 2 | 5 | 1 | 3 | Exploratory |
| 43000007 | ML for mouse acute toxicity prediction | 3 | 1 | 2 | 2 | 4 | Exploratory |
| 42999792 | Paraneoplastic disease in thymic tumors (Denmark) | 4 | 4 | 3 | 4 | 4 | Exploratory |
| 43000096 | AI-ECG for structural heart disease (PROVAR+, n=3,779) | 7 | 7 | 7 | 6 | 6 | Exploratory→ Validated |
| 42999616 | ADCs in perioperative NSCLC treatment | 5 | 5 | 7 | 3 | 2 | Exploratory |
| 43000039 | HIV, obesity, and stigma | 5 | 4 | 7 | 3 | 2 | Exploratory |
| 43000169 | Sleep and sarcopenia in peritoneal dialysis | 5 | 4 | 4 | 3 | 4 | Exploratory |
| 42999529 | Opisthorchis viverrini spatial risk ML | 5 | 3 | 4 | 3 | 5 | Exploratory |
| 43000120 | Computerised decision support in anaesthesia (Scandinavia) | 4 | 5 | 5 | 4 | 4 | Exploratory |
| 42999387 | Phenotypic clustering in end-stage liver disease | 5 | 4 | 4 | 3 | 4 | Exploratory |
| 42999985 | Oncology drug development transformation in China | 4 | 4 | 6 | 3 | 2 | Exploratory |
| 43000151 | Lymphoma treatment in older adults — Japan | 4 | 5 | 5 | 3 | 2 | Exploratory |
| 42999898 | Remote presence virtual care in medical education | 4 | 4 | 5 | 4 | 3 | Exploratory |
| 42999553 | Copper homeostasis for cancer immunotherapy (animal) | 5 | 2 | 4 | 1 | 3 | Exploratory |
| 43000195 | Multigene assays in breast cancer prognosis | 5 | 5 | 7 | 5 | 2 | Exploratory |
| 42999988 | Thymectomy extent and immune recovery in neonates | 6 | 5 | 3 | 3 | 3 | Exploratory |
| 42999840 | PPP2R1A in hepatocellular carcinoma (in vitro) | 5 | 2 | 5 | 1 | 3 | Exploratory |
| 42999809 | State of Precision Oncology in Australia | 4 | 4 | 5 | 3 | 2 | Exploratory |
| 42999902 | Salvage HDR brachytherapy for prostate cancer recurrence | 5 | 6 | 5 | 5 | 5 | Exploratory |
| 43000194 | Apple-derived exosome microneedling RCT (n=21) | 4 | 3 | 4 | 4 | 4 | Exploratory |
| 42999917 | 3D multispectral + ML for plant stress (non-clinical) | 2 | 1 | 1 | 1 | 4 | Exploratory |
| 42999796 | Precision oncology for NSCLC in Latin America | 5 | 5 | 7 | 3 | 2 | Exploratory |
| 42999037 | Gut microbiome and Alzheimer's (Drosophila model) | 5 | 2 | 7 | 1 | 3 | Exploratory |
| 42999937 | Glycomics + ML for osteoarthritis biomarkers | 6 | 4 | 6 | 3 | 4 | Exploratory |
| 42999851 | 2050 Kidney care disaster simulation | 4 | 4 | 5 | 2 | 2 | Exploratory |
| 43000088 | Deep learning for implant bone loss measurement (n=144) | 5 | 5 | 5 | 5 | 4 | Exploratory |
| 43000204 | Cyanine photosensitizer pyroptosis (animal) | 5 | 2 | 4 | 1 | 3 | Exploratory |
| 43000149 | AML treatment in older adults — Japan | 4 | 5 | 5 | 3 | 2 | Exploratory |
| 43000152 | HSCT in older adults — expanding indications Japan | 4 | 5 | 5 | 3 | 2 | Exploratory |
| 42999685 | ML for prostate radiotherapy toxicity prediction | 6 | 6 | 6 | 4 | 5 | Exploratory |
| 42999935 | CT-derived vBMD for opportunistic osteoporosis screening | 6 | 7 | 7 | 6 | 5 | Exploratory→ Validated |
| 42999631 | Extracellular vesicles in respiratory disease | 5 | 4 | 6 | 2 | 3 | Exploratory |
| 42999892 | Metastasis-directed therapy in de novo metastatic NPC | 6 | 6 | 4 | 4 | 5 | Exploratory |
| 43000106 | AI for rumen microbiome methane mitigation (animal) | 4 | 1 | 3 | 2 | 3 | Exploratory |
| 43000009 | Lemongrass EGFR binding (in vitro) | 2 | 1 | 2 | 1 | 2 | Exploratory |
| 42999678 | SGLT1 inhibition in cystic fibrosis | 6 | 5 | 4 | 2 | 2 | Exploratory |
| 42999614 | Hepatic steatosis distribution on lung cancer screening CT | 4 | 4 | 5 | 4 | 5 | Exploratory |
| 42999547 | LCH in child presenting as post-traumatic swelling (case) | 3 | 3 | 2 | 3 | 2 | Exploratory |
| 42999773 | CRISPR/Cas9 for LAD-I (in vitro) | 6 | 3 | 3 | 1 | 3 | Exploratory |
| 43000146 | PRCA + polymyalgia rheumatica case report | 4 | 4 | 2 | 3 | 2 | Exploratory |
| 43000147 | Myeloma with abducens palsy (case report) | 3 | 3 | 2 | 2 | 1 | Exploratory |
| 42999338 | Imaging biomarkers for radiotherapy side effects (preprint) | 5 | 5 | 6 | 3 | 3 | Exploratory |
| 42999708 | Neoadjuvant FOLFOXIRI in colon cancer (case) | 4 | 4 | 5 | 3 | 2 | Exploratory |
| 42999039 | C. difficile screening in IBD (colonoscopy) | 5 | 5 | 5 | 4 | 4 | Exploratory |
| 42999646 | Surgical conversion after ALK-TKI in N3 NSCLC (3 cases) | 5 | 5 | 5 | 3 | 2 | Exploratory |
| 43000064 | HA-NLC delivery of APOBEC3B siRNA + gemcitabine (in ovo) | 5 | 2 | 4 | 1 | 3 | Exploratory |
| 42999753 | Cardiac microcoil migration after lung localization (case) | 4 | 4 | 3 | 4 | 2 | Exploratory |
| 42999938 | Geographic atrophy pharmacotherapy update | 5 | 5 | 6 | 3 | 2 | Exploratory |
| 43000188 | Lean body mass and GLP-1 — dietary protein (title only) | — | — | — | — | — | Title-only; insufficient for scoring |
| 42999519 | Severe obesity and reverse TSA dislocation risk | 4 | 5 | 6 | 6 | 5 | Validated |
| 42999371 | GABBR1 as cuproptosis biomarker in pancreatic cancer | 6 | 3 | 5 | 2 | 3 | Validated (bioinformatic) |
| 43000185 | GLP-1 RAs on hyperuricemia (meta-analysis) | 7 | 7 | 7 | 7 | 6 | [already scored above, article 14] |